X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (84) 84
infectious diseases (66) 66
male (66) 66
female (65) 65
adult (59) 59
index medicus (47) 47
middle aged (43) 43
immunology (36) 36
hiv infections - drug therapy (31) 31
thailand (29) 29
microbiology (28) 28
treatment outcome (25) 25
aged (23) 23
hiv (19) 19
infections (19) 19
drug therapy (17) 17
drug therapy, combination (17) 17
human immunodeficiency virus--hiv (17) 17
thailand - epidemiology (17) 17
anti-hiv agents - therapeutic use (16) 16
mortality (16) 16
adolescent (15) 15
clinical trials (14) 14
antiretroviral drugs (13) 13
cd4 lymphocyte count (13) 13
hiv infections - virology (13) 13
tenofovir (13) 13
virology (13) 13
health aspects (12) 12
hiv-1 - drug effects (12) 12
risk factors (12) 12
ritonavir - therapeutic use (12) 12
anti-bacterial agents - therapeutic use (11) 11
anti-hiv agents - administration & dosage (11) 11
care and treatment (11) 11
disease (11) 11
hiv infections - complications (11) 11
infection (11) 11
prospective studies (11) 11
research (11) 11
therapy (11) 11
viral load (11) 11
antiretroviral therapy, highly active (10) 10
double-blind method (10) 10
drug administration schedule (10) 10
pharmacology & pharmacy (10) 10
ritonavir - administration & dosage (10) 10
tropical medicine (10) 10
abridged index medicus (9) 9
adenine - analogs & derivatives (9) 9
adults (9) 9
antiretroviral therapy (9) 9
emtricitabine (9) 9
epidemiology (9) 9
highly active antiretroviral therapy (9) 9
hiv infection (9) 9
melioidosis (9) 9
melioidosis - drug therapy (9) 9
patients (9) 9
retrospective studies (9) 9
rna, viral - blood (9) 9
anti-hiv agents - adverse effects (8) 8
ceftazidime (8) 8
dosage and administration (8) 8
drug resistance (8) 8
fluconazole (8) 8
lopinavir (8) 8
mutation (8) 8
public, environmental & occupational health (8) 8
ritonavir - adverse effects (8) 8
sepsis (8) 8
tuberculosis (8) 8
adenine - therapeutic use (7) 7
aids (7) 7
aids/hiv (7) 7
antibiotics (7) 7
atazanavir sulfate (7) 7
bacteria (7) 7
drug dosages (7) 7
efavirenz (7) 7
hiv protease inhibitors - administration & dosage (7) 7
hiv protease inhibitors - therapeutic use (7) 7
infectious disease (7) 7
organophosphonates - therapeutic use (7) 7
pyridines - therapeutic use (7) 7
reverse transcriptase inhibitors - administration & dosage (7) 7
studies (7) 7
young adult (7) 7
adenine - administration & dosage (6) 6
antifungal agents - therapeutic use (6) 6
article (6) 6
cryptococcal meningitis (6) 6
deoxycytidine - analogs & derivatives (6) 6
hiv-1 (6) 6
hiv-1 - genetics (6) 6
medicine, general & internal (6) 6
oligopeptides - administration & dosage (6) 6
oligopeptides - therapeutic use (6) 6
organophosphonates - administration & dosage (6) 6
pharmacokinetics (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 7, pp. 828 - 837
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9639, pp. 646 - 655
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9572, pp. 1519 - 1527
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 383, Issue 9919, pp. 807 - 814
Journal Article
Expert Review of Anti-infective Therapy, ISSN 1478-7210, 09/2009, Volume 7, Issue 7, pp. 801 - 805
With the introduction of combination antiretroviral therapy (cART), there have been dramatic reductions in mortality and morbidity of HIV-1-infected patients.... 
lopinavir-ritonavir | antiretroviral therapy-naive patients | atazanavir-ritonavir | Antiretroviral therapy-naive patients | Atazanavir-ritonavir | Lopinavir-ritonavir | Humans | Oligopeptides - adverse effects | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Clinical Trials, Phase III as Topic | Deoxycytidine - therapeutic use | Pyridines - adverse effects | Adenine - adverse effects | Multicenter Studies as Topic | Ritonavir - adverse effects | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Lopinavir | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Organophosphonates - adverse effects | Treatment Outcome | Adenine - administration & dosage | Randomized Controlled Trials as Topic | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Deoxycytidine - analogs & derivatives | Antiviral agents | Highly active antiretroviral therapy | Care and treatment | Proteases | Mortality | HIV patients | HIV (Viruses) | Health aspects | Anti-HIV agents | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 8, pp. 725 - 734
Journal Article
Southeast Asian Journal of Tropical Medicine and Public Health, ISSN 0125-1562, 05/2018, Volume 49, Issue 3, pp. 465 - 468
Atrial myxomas may rarely become infected, usually with gram-positive cocci. We report here the case of 34-year-old Thai man who presented with fever for 10... 
Influenzae | Infected atrial myxoma | H. influenzae | infected atrial myxoma | INFECTIOUS DISEASES | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | CLINICAL PRESENTATION | ENDOCARDITIS | CARDIAC MYXOMA | TROPICAL MEDICINE | Literature reviews | Myxoma | Cocci | Gram-positive cocci | Antibiotics | Fever
Journal Article
Southeast Asian Journal of Tropical Medicine & Public Health, ISSN 0125-1562, 09/2014, Volume 45, Issue 5, pp. 1125 - 1125
Disseminated nontuberculous mycobacterial (NTM) infection is the most common feature in patients positive for anti-interferon-gamma autoantibody. The condition... 
Journal Article
Southeast Asian Journal of Tropical Medicine and Public Health, ISSN 0125-1562, 09/2014, Volume 45, Issue 5, p. 1125
  Disseminated nontuberculous mycobacterial (NTM) infection is the most common feature in patients positive for anti-interferon-gamma autoantibody. The... 
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2018, Volume 13, Issue 11, p. e0208053
Journal Article
Journal Article